China
Can the 'Pharmacy of the World' Survive Its Own Scandals?
In late September and early October 2025, children in the central Indian state of Madhya Pradesh began arriving at hospitals with the same grim trajectory:...
June 08, 2026 | Analysis
Mabwell's First In Class Autoimmune Antibody 9MW5211 Wins China Clinical Trial Approval for IBD
Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently...
June 08, 2026 | News
LongBio Pharma Debuts on Hong Kong Exchange With HK$10.7 Billion Valuation
LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases in China, liste...
June 08, 2026 | News
Vcare PharmaTech Secures China Approval for Next Generation TRK Inhibitor Eratrectinib in NTRK Fusion Positive Solid Tumours
NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the...
June 08, 2026 | News
DHCG And Altruist Biologics Partner To Accelerate Global Biologics Development Through China Manufacturing Expertise
Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist...
June 05, 2026 | News
Correctseq Reports 15 Month Crisis Free Outcome in First Sickle Cell Disease Patient Treated With CS 206
CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for ...
June 04, 2026 | News
Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines
Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immun...
June 04, 2026 | News
Innovation Powerhouse or Inflated Bubble? Reading China’s First-in-Class Boom
A decade ago, the phrase “Chinese first-in-class drug” would have drawn a raised eyebrow in any Western boardroom. China made generics, copied ...
June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com
XtalPi Earns Second Milestone Payment As AI Drug Discovery Alliance With DoveTree Gains Momentum
XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical c...
June 02, 2026 | News
Lynk Pharmaceuticals Advances LNK01004 Into Phase II Trials For Vitiligo And Chronic Hand Eczema
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...
June 02, 2026 | News
ImmVira Reports 100% Complete Response Rate With MVR T3011 In BCG Unresponsive Bladder Cancer
ImmVira Group announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 Ameri...
June 02, 2026 | News
Lilly Secures Global Rights To Hanmi's Sonefpeglutide In Potential $1.26 Billion Deal
Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications Hanmi Pharm. Co., Ltd. ("Hanmi") announced that they have entered i...
June 02, 2026 | News
China Developed Anaesthetic Cipepofol Secures US FDA Approval, Marking Global Breakthrough
Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical ...
June 02, 2026 | News
Pfizer And Innovent Biologics Forge Global Oncology Alliance Covering 12 Cancer Programs
Pfizer Inc. and Innovent Biologics, Inc. announced the companies have entered into a strategic global licensing and collaboration agreement for the r...
June 01, 2026 | News
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
Editor Picks
